Emma Brofsky is a Scientific Program Analyst in the Division of Cancer Prevention at the National Cancer Institute. She serves as Project Manager for two research networks, the US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet), focused on collaborations to evaluate approaches for prevention of HPV-related cancers in people living with HIV, and the HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network, focused on pragmatic clinical trials to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. In addition, she supports other projects within the Breast and Gynecological Cancer Research Group and the Division.

Emma received a Bachelor in Biological Sciences from Cornell University and a Master of Science in Public Health in Global Disease Epidemiology and Control from the Johns Hopkins Bloomberg School of Public Health. She has experience working with local, state, and federal public health agencies as well as in international field settings on projects related to emerging infectious disease response, program implementation, and maternal and child health.

Professor Schreiber has been a pivotal figure in validating and advancing the theory of cancer immunosurveillance and immunoediting, the processes by which our immune systems monitor, control, and shape the development of cancer. 

His honours include the SITC - Richard V Smalley Memorial Award (2023), the AACR-Princess Takamatsu Memorial Lectureship Award (2023), 2024 Senior Scientist Recipient of the Innovators in Science Award Cancer in Immunology, Member NCI-Cancer Research UK Grand challenges Scientific Advisory Committee (2024), Lifetime Achievement Award: Immunotherapy of Cancer Association (2025) and the Distinguished Faculty Award Washington University in St. Louis (2025). Professor Schreiber also received the 2001 William B. Coley Award for Distinguished Research in Basic and Tumour Immunology, the 2014 AACR-CRI Lloyd J. Old Award in Cancer Immunology, and the 2017 Balzan Prize. He has been elected to the National Academy of Sciences and the American Association for the Advancement of Science. His current work continues to characterize how various immune signalling pathways, as well as tumour mutations, influence anti-tumour immune responses.

Zeev Blumenfeld is MD for Hebrew University and Hadassah Medical School, Jerusalem, and he is the Director of Reproductive Endocrinology for the department Obstetrics & Gynecology. He worked as a Director in the year 2010 for Reproductive Endocrinology; he is a Senior Physician for Reproductive Endocrinology and Infertility, OB/GYN. He has an extensive and vast teaching experience in the field of "Reproductive Endocrinology".

He taught Director in Endocrinology Course for medical & graduate students, Director of “Physiology of Reproduction” course. He worked as a Reviewer for many scientific Journals. He also has membership for International and National professional societies. He Elected as a member of the "Society for Gynecologic Investigation". Worked as Editor in Chief- ‘Clinical Medicine Insight: Reproductive Health’, "Journal of Reproductive Biology and Health".

Zeev Blumenfeld advanced studies: 1983-1985 Fellowship in Reproductive Endocrinology in the Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco,

1993- Exon-Intron Workshop on Molecular Biology - Recombinant DNA Methodology, 1993.

2014-   Completed the program of GCP & clinical trials management for PI's. He had 27 Publications.